Table 1.
Baseline characteristics of the 28 patients with CD enrolled in the study.
| Overall population | |
|---|---|
| n = 28 | |
| Age at inclusion (years), mean ± SD | 38.07 ± 13.1 |
| Female gender, n (%) | 19 (67.9%) |
| Active smokers, n (%) | 7 (25.0%) |
| Montreal classification | |
| CD location | |
| L1, n (%) | 10 (35.7%) |
| L2, n (%) | 3 (10.7%) |
| L3, n (%) | 14 (50.0%) |
| CD behaviour | |
| B1, n (%) | 21 (75.0%) |
| B2, n (%) | 4 (14.3%) |
| B3, n (%) | 2 (7.1%) |
| Current medications | |
| 5-ASA | 2 (7.1%) |
| Corticoids | 1 (3.6%) |
| Thipurines | 4 (14.3%) |
| Methotrexate | 1 (3.6%) |
| Infliximab | 2 (7.1%) |
| Adalimumab | 4 (14.3%) |
| Vedolizumab | 0 (0.0%) |
| CDAI, mean ± SD | 105.0 ± 80.95 |
| CDEIS, mean ± SD | 2.3 ± 2.9 |
| Calprotectin, mean (µg/g) ± SD | 154.81 ± 286.16 |
| Chitinase 3-Like 1, mean (ng/g) ± SD | 40.96 ± 56.95 |
SD standard deviation, n number, CD Crohn’s disease, CDAI Crohn Disease Activity Index, CDEIS Crohn’s disease endoscopic index of severity, 5-ASA acide 5-aminosalicylique.